ultra-rare-diseas focu allow alexion captur
updat forecast estim feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
valuat growth profit
methodolog valu compani
alexion pharmaceut ultra-rare-diseas focu allow
compani captur substanti price power area high
eculizumab approv disease-modifi
treatment paroxysm nocturn hemoglobinuria
atyp hemolyt urem syndrom potenti
soliri expand indic two product
ultra-rar metabol disord pipelin target orphan
opportun think alexion well posit retain lead
statu nich market
key soliri success strong price power drug
dramat life-sav effect pnh ahu patient compris
peopl north america europ despit
small popul soliri high price
annual need lifelong use quickli turn drug
blockbust alexion focus soliri label expans
complement-medi diseas receiv approv
subtyp myasthenia gravi anoth rare diseas
anoth pivot trial on-going neuromyel optica spectrum
pipelin competit grow drug manufactur flock
lucr autoimmun market alexion first-mov statu
next-gener pipelin mitig risk addit firm
continu drive growth identif new
patient given lack awar mani ultra-rar diseas
grossli underdiagnos alexion special salesforc
strong entrench patient doctor rais barrier
entri allow maintain quasi-monopoli hold
diseas space
outsid complement inhibitor franchis alexion portfolio
includ strensiq gain approv hypophosphatasia
late kanuma lysosom acid lipas defici soon
overal think soliri favor competit posit
drive solid financi result forese futur
sale strensiq kanuma begin add meaning revenu
alexion high degre product concentr key risk
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
special develop market drug
life-threaten medic condit blockbust product soliri
approv therapi paroxysm nocturn hemoglobinuria
atyp hemolyt urem syndrom two ultra-rar blood disord
recent approv gener myasthenia gravi strensiq kanuma
target ultra-rar metabol diseas alexion pipelin target area
high unmet need complement-medi disord
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit feb
maintain fair valu estim alexion
incorpor fourth-quart result guidanc
model slightli lower estim soliri
growth given higher-than-expect impact on-going
competitor molecul soliri sale
howev impact off-set lower expect
oper cost near term
valuat firm remain primarili driven
expans soliri franchis alexion profit
cash flow gener power continu grow
compani expand abroad broaden soliri reach
patient new indic averag model
compound annual top-lin growth littl
bottom-lin growth firm next five year
believ soliri franchis could see peak sale
billion global growth patient pnh ahu
potenti label expans addit autoimmun
indic think strensiq kanuma peak sale
potenti billion million respect
ultra-rare-diseas indic expect gross
margin stay around forecast period
oper margin could near next year
drug move pipelin compani
leverag salesforc across broader revenu base
execut restructur plan
given alexion product concentr believ
compani merit high uncertainti rate bull case
assum alexion succe expand soliri label
addit indic receiv littl pushback
payer allow firm captur high price point
drug multipl market case assum
peak sale billion fair valu estim
would increas roughli per share bear case
assum cost pressur payer threat
gener biolog forc alexion lower price lose
market share time also assum soliri label
includ current approv indic scenario
pipelin contribut futur sale soliri sale
peak less billion think compani
valu would fall per share
believ alexion patent-protect portfolio
ultra-rare-diseas drug well clinic develop
target addit indic area high unmet
alexion focu ultra-rare-diseas market allow
autoimmun metabol diseas target
compani drug pipelin disease-modifi
treatment option face dire prognos caus
diseas slightli differ patient pnh
ahu devast uncontrol activ
immun system specif part call complement
result chronic destruct red blood cell lead
blood clot organ failur thirty-f percent pnh
patient die within five year ahu patient
progress end-stag renal diseas lal-d
patient miss key enzym critic metabol
function case onset diseas start
birth patient die organ failur within year given
access alexion drug matter life death
mani alexion treat diagnos popul
per-pati cost astronom overal
burden countri healthcar system small
number affect patient extrem limit soliri
tout one expens drug world
price may vari countri countri estim
annual averag cost drug
around
per patient strensiq kanuma
price nontrivi annual sum
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
composition-of-matt patent expir kanuma
orphan drug exclus european union
respect addit viabl
soliri biosimilar competitor initi
phase trial acknowledg alexion portfolio
antibodi soliri recombin protein strensiq
kanuma -- histor difficult
manufactur small-molecul drug howev
believ biosimilar manufactur develop
progress far enough end decad erod
current advantag emphas moat rate
rest alexion patent
brand competit mount intang
gener alexion first-mov statu pipelin
creat high barrier entri closest pipelin threat
alexion complement franchis phase
small sampl size competitor molecul
aim conveni self-administ
subcutan inject soliri pnh ahu
patient need travel clinic everi two week receiv
infus medicin subcutan less
frequent dose would reliev larg burden patient
soliri strong efficaci creat high bar new entrant
akari least year away pivot
phase result alexion next-gener platform
quickli progress develop next-gener
soliri expect extend dose frequenc
least monthli longer pivot trial pnh
ahu underway expect market launch earli
believ higher probabl
success receptor/monoclon antibodi interact
alreadi prove success mechan target
complement system soliri compani also
suit candid target differ part
complement cascad subcutan
early-stag develop high level cash
per patient respect howev drug
clear disease-modifi benefit help justifi high
price facilit reimburs payer public
privat addit mani patient alexion
drug live normal near-norm life span
chronic natur alexion target diseas grow
patient popul better surviv rate mean
market pnh ahu lal-d expand
compani strong patent portfolio limit risk
biosimilar competit given attract diseas market
alexion oper surpris competitor
clamor enter space compani
well insul lengthi patent portfolio intang
asset underpin alexion narrow moat rest heavili
patent soliri previous extend
european market unit state
recent patent addit take timelin even
opportun lengthen patent life alexion portfolio
earliest gener competit erod strensiq
sale would
drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
forese futur believ alexion diversif
ultra-rar metabol diseas allow firm leverag
commerci infrastructur expertis derisk
sourc revenu
test soliri
addit autoimmun
indic includ patient neuromyel optica
spectrum disord refractori myasthenia gravi
howev believ soliri expans differ
diseas indic merit posit moat trend
expect biosimilar competitor would abl
quickli gain approv relev indic
mechan action prove safe effect one
alexion sale could also face drastic brand eros
competitor drug reach market subcutan
administr top similar efficaci safeti profil
soliri howev believ alexion long-act
candid although subcutan
inject reach market first provid
attract profil less frequent dose proven
mechan action alexion also subcutan
version early-stag develop
gener would like see opportun
diversif greater acceler pipelin
develop upgrad alexion posit moat
gener alexion capac buy two
smaller competitor need
competitor even alexion extent face longer
timelin challeng enrol regulatori
condit clinic trial given rariti diseas
avail effect treatment
launch alexion first-gener product howev
alexion ad benefit already-establish
patient investig relationship leverag
acceler enrol timelin commerci
roll-out product addit alexion special
salesforc strong entrench patient
doctor allow maintain quasi-monopoli
nich diseas area forese futur given
averag doctor never encount patient
one ultra-rar diseas career take uniqu
strategi identifi invest time money
educ correct contact believ alexion hold
lead posit lucr autoimmun metabol
ultra-rare-diseas market forese futur
perspect grow pipelin competitor
complement-medi diseas space balanc
alexion portfolio next-gener candid
stabl trend rate rest abil alexion
pipelin asset stay one step ahead major competit
compani demonstr abil intern develop
complement-rel drug like soliri success
commerci seen launch strensiq give us
confid alexion pipelin complement drug
drug strensiq kanuma brand competit
horizon tout long patent protect
keep particular market dynam stabl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ogiven statu orphan drug strong efficaci
soliri garner one highest price tag
payer market share
opnh ahu rare diseas alexion
alreadi identifi easili identifi
patient soliri high growth rate could level
firm unabl expand new market
oalexion abl leverag rare-diseas
expertis infrastructur effici expand
result rise profit margin time
indic
oalexion solid balanc sheet grow cash
balanc provid financi flexibl
abil fund pipelin possibl
owith one highest price tag soliri could
becom target drug price concern could
encount increas price pressur futur
oalexion overpaid synageva acquisit
could depress return invest capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
alexion strong free cash flow gener thank
billion cash cash equival market
secur follow announc billion
acquisit synageva alexion ad billion
debt financ transact current debt level hover
around billion confid compani
abil pay servic debt next
year believ sale soliri franchis
suffici fund intern capit requir includ
clinic pipelin
advanc
commerci
market portfolio
forese futur anticip compani
priorit business-develop activ bolster
alexion face high degre product concentr
risk ad diversif strensiq kanuma
reduc alexion depend soliri
anticip metabol portfolio sale drastic lower
alexion product concentr forecast
soliri sale still account total product
revenu nearli compound
risk investig soliri sale practic late
probe
potenti fraudul
diagnos brazilian polic soliri commerci
success could stunt high price point meet payer
resist also increas rhetor
around drug price congress histor
lacklust develop drug polici passabl
effect howev rise high-deduct
plan scrutini health cost drug price
market may face pressur futur
account nearli alexion total sale launch
competitor molecul conveni method
dose could also captur materi portion soliri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market share pois reach market
monthli intraven dose competit failur
meet timelin could provid window competitor
launch subcutan version alexion
robust clinic program expand soliri differ
indic mount competit complement-medi
diseas space could undermin effort recur
manufactur issu compani rhode island
manufactur facil compound concentr risk
alexion receiv food drug administr warn
letter addit observ
swiftli address howev episod
highlight risk compani suppli chain
depend one product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
fidel manag research compani
share
fund
share
fund
award alexion standard stewardship rate
abrupt departur ceo david hallal cfo vika sinha
late decemb amid soliri sale practic
investig david brennan took lead interim
ludwig hantson appoint ceo march
earli judg hantson think
compani solid hand hantson serv briefli ceo
baxalta rare-diseas drug busi spun
baxter sold shire year later
baxalta hantson senior leader baxter built
pharma career novarti johnson johnson
surpris see hantson clean hous
revamp manag team compani move past
soliri sale practic investig alexion new team
includ paul clanci chief financi offic brian goff
chief commerci offic john orloff head research
develop indrani franchini chief complianc
offic anne-mari law chief human resourc
offic pleas see depth industri
experi new leadership team bring tabl
sale investig result immateri chang
alexion file would consid downgrad
stewardship rate intern control issu persist
posit alexion futur view team
capital-deploy standpoint think alexion
decis acquir enobia pharma synageva
made strateg sens strensiq kanuma fit well
within alexion strategi focus ultra-rar diseas
devast effect current disease-modifi
treatment alexion abl leverag exist
infrastructur market drug work physician
better identifi ultra-rar diseas howev
concern high price compani paid
synageva cautiou overal valu creation
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
deal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
alexion gear futur maintain fve
maintain fair valu estim alexion
pharmaceut follow compani third-quart
result manag narrow top-lin guidanc
high end origin rang thank strong underli
demand soliri reduc full-year earn guidanc
reflect charg relat restructur plan
previous announc alexion divest sever
pipelin drug close manufactur plant allow
focus cost disciplin research effort
increas soliri sale estim slightli
off-set updat pace margin expans
estim fall toward top end manag
advantag given patent-protect portfolio ultra-rare-
diseas drug promis next-gener soliri
candid believ firm need bolster post-
third-quart soliri sale increas year
year alexion lead drug sale declin sequenti
basi expect anticip healthi
underli demand soliri two establish autoimmun
indic continu off-set increas
enrol alexion pivot trial evalu next-gen
later subcutan expect
phenomenon weigh soliri sale even drug
ramp recent approv gener myasthenia
gravi patient popul posit anti-acetylcholin
antibodi gener mg autoimmun disord
disrupt nerv respons normal muscl
contract present opportun
unit state patient program
expect roll extens trial last
drug potenti receiv approv first half
although data expect second quarter next year
kanuma strensiq alexion two rare-metabolic-diseas
drug continu post steadi slow-mov sale
quarter drug repres small opportun
alexion soliri label expans remain largest driver
valuat pivot data evalu soliri
multipl sclerosi expect present
anoth top-lin opportun firm gener view
compani restructur effort net posit add
focu non-soliri pipelin howev sever
pipelin candid cull believ tuck-in
acquisit crucial alexion rebuild early-
rais alexion fve follow restructur
plan lower cost sep
rais fair valu estim alexion
pharmaceut per share reflect
expect cost save manag restructur
plan still believ narrow-moat compani
under-valued hasnt appear recov
biotech slide amid turmoil soliri sale practic
investig manag shakeup
detail depriorit certain pipelin program
favor focus strategi complement
hematolog nephrolog neurolog metabol
disord compani expect save million
annual thank focus research
develop strategi lead reduct
employe base close consolid
manufactur site better-ration administr
expens model near-term reduct oper
expens restructur cost result
save alexion plan earmark million
year rebuild pipelin small deal
optimist futur soliri label expans next-
gener believ bolster pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
alexion headquart move boston biotech hub
connecticut attract talent partnership
believ alexion nich expertis first-mov statu
complement provid attract base compani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
